Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Viral factors in non-progression.

Wang B.

Front Immunol. 2013 Dec 24;4:355. doi: 10.3389/fimmu.2013.00355. Review.

2.

HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex.

Wang X, Singh S, Jung HY, Yang G, Jun S, Sastry KJ, Park JI.

J Biol Chem. 2013 May 31;288(22):15474-80. doi: 10.1074/jbc.M112.416735. Epub 2013 Apr 23.

3.

Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.

Münk C, Jensen BE, Zielonka J, Häussinger D, Kamp C.

Viruses. 2012 Nov 14;4(11):3132-61. doi: 10.3390/v4113132. Review.

4.

Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.

Albin JS, Haché G, Hultquist JF, Brown WL, Harris RS.

J Virol. 2010 Oct;84(19):10209-19. doi: 10.1128/JVI.00632-10. Epub 2010 Aug 4.

5.

The relationship between antibody to R7V and progression of HIV type 1 infection.

Margolick JB, Da Costa Castro JM, Sanchez A, Gemrot F, Phair JP, Jamieson BD, Rinaldo CR, Jacobson LP.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):389-94. doi: 10.1089/aid.2009.0101.

6.

HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Andersen JL, Le Rouzic E, Planelles V.

Exp Mol Pathol. 2008 Aug;85(1):2-10. doi: 10.1016/j.yexmp.2008.03.015. Epub 2008 Apr 25. Review.

7.

Modulation of beta-catenin and E-cadherin interaction by Vpu increases human immunodeficiency virus type 1 particle release.

Salim A, Ratner L.

J Virol. 2008 Apr;82(8):3932-8. doi: 10.1128/JVI.00430-07. Epub 2008 Feb 6.

8.
9.

Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo.

Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V.

J Virol. 2006 Nov;80(21):10407-18. Epub 2006 Sep 6.

10.

HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy.

Chui C, Cheung PK, Brumme CJ, Mo T, Brumme ZL, Montaner JS, Badley AD, Harrigan PR.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):615-8.

11.

Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification.

Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD.

PLoS Pathog. 2005 Sep;1(1):e6. Epub 2005 Jul 22.

12.

Pervasive genomic recombination of HIV-1 in vivo.

Shriner D, Rodrigo AG, Nickle DC, Mullins JI.

Genetics. 2004 Aug;167(4):1573-83.

13.

Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis.

Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, Yao XJ, Lynch D, Pilon AA, Hawley N, Kim JE, Chen Z, Montpetit M, Sanchez-Dardon J, Cohen EA, Badley AD.

J Clin Invest. 2003 May;111(10):1547-54.

14.

The mitochondriotoxic domain of Vpr determines HIV-1 virulence.

Brenner C, Kroemer G.

J Clin Invest. 2003 May;111(10):1455-7. No abstract available.

15.

Mitochondrial apoptosis and the peripheral benzodiazepine receptor: a novel target for viral and pharmacological manipulation.

Castedo M, Perfettini JL, Kroemer G.

J Exp Med. 2002 Nov 4;196(9):1121-5. Review. No abstract available.

16.

Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.

Jekle A, Schramm B, Jayakumar P, Trautner V, Schols D, De Clercq E, Mills J, Crowe SM, Goldsmith MA.

J Virol. 2002 Jul;76(14):6966-73.

17.

Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Ikuta K, Suzuki S, Horikoshi H, Mukai T, Luftig RB.

Microbiol Mol Biol Rev. 2000 Dec;64(4):725-45. Review.

18.
19.

Supplemental Content

Support Center